Compare EDD & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDD | SMTI |
|---|---|---|
| Founded | 2007 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.1M | 313.5M |
| IPO Year | N/A | 2008 |
| Metric | EDD | SMTI |
|---|---|---|
| Price | $5.81 | $34.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 443.3K | 344.1K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,586,976.00 |
| Revenue This Year | N/A | $17.31 |
| Revenue Next Year | N/A | $12.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $4.96 | $16.05 |
| 52 Week High | $6.18 | $35.70 |
| Indicator | EDD | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 81.05 |
| Support Level | $5.73 | $20.47 |
| Resistance Level | $6.03 | $34.33 |
| Average True Range (ATR) | 0.08 | 0.74 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 16.60 | 97.65 |
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.